Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01364779|
Recruitment Status : Completed
First Posted : June 2, 2011
Last Update Posted : May 15, 2013
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Chronic Kidney Disease|
|Study Type :||Observational|
|Actual Enrollment :||15 participants|
|Official Title:||Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
- prevalence of aspirin resistance in chronic kidney disease patients [ Time Frame: 2 years ]Blood drawn for the Accumetric test
- risk factors contributing to aspirin resistance in this population. [ Time Frame: 2 years ]risk factors
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Patients with known structural kidney disease as evident by history or by urinalysis and CKD stage III or IV determined by MDRD formula and who are taking aspirin.
- Younger than 18 years of age.
- Bleeding disorder or myeloproliferative disorders.
- Thrombocytopenia with platelets < 100.000.
- Acute hemorrhagic disease.
- A recent history of receipt of platelet glycoprotein IIb/IIIa blockers.
- Liver disease as evident by abnormal liver function and total bilirubin > 2mg/dl.
- use of anticoagulation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01364779
|United States, New York|
|staten island University Hospital nephrology clinic|
|Staten Island, New York, United States, 10305|
|Principal Investigator:||Suzanne El_Sayegh, MD||Staten Island University Hospital|
|Responsible Party:||Suzanne El-Sayegh, Nephrology Attending, Assoc. Chair of Medicine, Northwell Health|
|Other Study ID Numbers:||
|First Posted:||June 2, 2011 Key Record Dates|
|Last Update Posted:||May 15, 2013|
|Last Verified:||May 2013|
Chronic kidney disease
Renal Insufficiency, Chronic
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Male Urogenital Diseases